Fgf20-KO Mouse
Common Name
Fgf20-KO
제품 ID
S-KO-15313
Backgroud
C57BL/6NCya
품종 계통계통 ID
KOCMP-80857-Fgf20-B6N-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Fgf20-KO Mouse (카탈로그 번호 S-KO-15313)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Fgf20-KO
품종 계통계통 ID
KOCMP-80857-Fgf20-B6N-VA
유전자명
제품 ID
S-KO-15313
유전자 별칭
Fgf4a
배경
C57BL/6NCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 8
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000034014
NCBI 전사체 ID
NM_030610
타겟 영역
Exon 1~3
유효 영역 크기
~7.6 kb
유전자 연구 개요
Fgf20, or Fibroblast growth factor 20, is a neurotrophic factor and a member of the FGF9 subfamily. Its receptors include FGFR4, FGFR3b, FGFR2b, and FGFRc splice forms. It is highly expressed in the adult brain and is expressed in various regions during embryonic development. Fgf20 is associated with multiple biological processes and human diseases [1].
Fgf20 knockout (KO) mouse models have shown a variety of phenotypes. For example, Fgf20 KO mice exhibit congenital deafness, lack of hair, small kidneys, and delayed mammary ductal outgrowth, indicating its role in inner ear, hair, kidney, and mammary gland development [1]. In the cochlea, FGF20-FGFR1 signaling through MAPK and PI3K controls sensory progenitor differentiation, as shown by experiments inhibiting pathways downstream of FGFR1 in cochlea explant cultures [2]. In spinal cord injury mouse models, recombinant human FGF20 was found to mitigate necroptosis, reduce neural functional deficits, and promote repair [3]. In a traumatic brain injury mouse model, FGF20 reduced neurofunctional deficits, brain edema, and neuroinflammation, protecting the blood-brain barrier integrity [5]. Fgf20 KO mice also show skeletal dysmorphology and mineralization defects, especially in the spine and fingers, indicating its role in skeletal development and bone homeostasis [7].
In conclusion, Fgf20 plays essential roles in multiple biological processes such as embryonic development, organogenesis, and neural repair. The study of Fgf20 using KO mouse models has provided insights into its functions in diseases like congenital deafness, Parkinson's disease, cancer, and inflammatory bowel disease, suggesting its potential as a therapeutic target in these disease areas [1,3,5,7].
References:
1. Van Greenen, Justine D, Hockman, Dorit. 2023. FGF20. In Differentiation; research in biological diversity, 139, 100737. doi:10.1016/j.diff.2023.10.005. https://pubmed.ncbi.nlm.nih.gov/38007375/
2. Su, Yutao, Yang, Lu M, Ornitz, David M. 2020. FGF20-FGFR1 signaling through MAPK and PI3K controls sensory progenitor differentiation in the organ of Corti. In Developmental dynamics : an official publication of the American Association of Anatomists, 250, 134-144. doi:10.1002/dvdy.231. https://pubmed.ncbi.nlm.nih.gov/32735383/
3. Cai, Xiong, Xie, Zhenwen, Zhao, Juan, Xu, Jiake, Zhu, Sipin. . FGF20 promotes spinal cord injury repair by inhibiting the formation of necrotic corpuscle P-MLKL/P-RIP1/P-RIP3 in neurons. In Journal of cellular and molecular medicine, 28, e70109. doi:10.1111/jcmm.70109. https://pubmed.ncbi.nlm.nih.gov/39676730/
4. Katoh, Masaru. 2018. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). In International journal of molecular medicine, 42, 713-725. doi:10.3892/ijmm.2018.3689. https://pubmed.ncbi.nlm.nih.gov/29786110/
5. Chen, Jun, Wang, Xue, Hu, Jian, Lin, Li, Li, Xiaokun. 2021. FGF20 Protected Against BBB Disruption After Traumatic Brain Injury by Upregulating Junction Protein Expression and Inhibiting the Inflammatory Response. In Frontiers in pharmacology, 11, 590669. doi:10.3389/fphar.2020.590669. https://pubmed.ncbi.nlm.nih.gov/33568994/
6. Wang, Xiaoli, Sun, Xiaoxuan, Zhang, Xiaona, Li, Hong, Xie, Anmu. 2017. Quantitative assessment of the effect of FGF20 rs12720208 variant on the risk of Parkinson's disease: a meta-analysis. In Neurological research, 39, 374-380. doi:10.1080/01616412.2017.1286542. https://pubmed.ncbi.nlm.nih.gov/28191856/
7. Dlugosova, Sylvie, Spoutil, Frantisek, Madureira Trufen, Carlos Eduardo, Sedlacek, Radislav, Prochazka, Jan. 2024. Skeletal dysmorphology and mineralization defects in Fgf20 KO mice. In Frontiers in endocrinology, 15, 1286365. doi:10.3389/fendo.2024.1286365. https://pubmed.ncbi.nlm.nih.gov/39129916/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
